Program Co-Leader - Gail A. Bishop, PhD, Professor, Microbiology and Internal Medicine
The Cancer Immunology and Immunotherapy Program consists of faculty investigators who are linked by common research interests in the functioning of the immune system, and how that system can be manipulated to help prevent or treat cancer and complications of cancer. The investigators in this program are working on problems that extend from fundamental molecular questions to those involving how recent advances in basic immunology can be translated into clinical utility for the treatment of cancer.
Although many of investigators in the Cancer Immunology and Immunotherapy Program are pursuing related questions, the individual research programs are diverse, allowing researchers in this program to attack basic biologic issues, and develop new clinical therapies, from many angles. Model systems being studied range from an evaluation of signaling properties of T and B cells, to increasing the efficacy of vaccines and immunotherapy in living animals, through the conduct of novel clinical trials related to cancer immunotherapy. Clinical applications, as a direct result of more basic investigations, have arisen from within the group and it is expected that this will continue.
Because of the diversity of research interests reflected within the membership of the Cancer Immunology and Immunotherapy Program, a wide range of technologies and approaches are available to investigators. Each of our investigators benefits from interactions with others in the program, as well as members of additional Cancer Center programs, resulting in a synergism yielding new insights, perspectives, and collaborative efforts.